Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma

European Journal of Haematology

Volumn 80, Issue 1, 2008, Pages 46-54

  Pennanen, Heli ^a,b   Kuittinen, Outi ^b   Turpeenniemi Hujanen, Taina ^b  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF OULU   (Finland)

Author keywords

Follow up; Gelatinase; Matrix metalloproteinase 2; Matrix metalloproteinase 2 tissue inhibitor of metalloproteinase 2 complex; Matrix metalloproteinase 9; Plasma marker; Tissue inhibitor of metalloproteinase 1; Tissue inhibitor of metalloproteinase 2

Indexed keywords

ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PREDICTIVE VALUE OF TESTS; RECURRENCE; REMISSION INDUCTION; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 37249005827     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00975.x     Document Type: Article

References (38)

1. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Ferme C. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996 78 : 1293 9.
2. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997 3 : 801 13.
3. Rodriguez AM. Factors that influence prognosis of intermediate-grade lymphomas at relapse. In : Cabanillas F, Rodriguez MA, eds. Advances in Lymphoma Research. Boston : Kluwer Academic Publishers, 1997 : 79 86.
4. Elis A, Blickstein D, Klein O, Eliav-Ronen R, Manor Y, Lishner M. Detection of relapse in non-Hodgkin's lymphoma: role of routine follow-up studies. Am J Hematol 2002 69 : 41 4.
5. Curran S, Murray GI. Matrix metalloproteinases in tumour invasion and metastasis. J Pathol 1999 189 : 300 8.
6. Fujimoto N, Ward RV, Shinya T, Iwata K, Yamashita K, Hayakawa T. Interaction between tissue inhibitor of metalloproteinases-2 and progelatinase A: immunoreactivity analysis. Biochem J 1996 313 : 827 33.
7. Strongin YA, Collier I, Bannikow G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72 kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995 270 : 5331 8.
8. Guedez L, Stetler-Stevenson WG, Wollf L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998 102 : 2002 10.
9. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998 92 : 1342 9.
10. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998 75 : 246 53.
11. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992 298 : 29 32.
12. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994 107 : 2373 9.
13. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005 83 : 287 97.
14. Talvensaari-Mattila A, Turpeenniemi-Hujanen T. High preoperative serum TIMP-1 is a prognostic indicator for survival in breast carcinoma. Breast Cancer Res Treatm 2005 89 : 29 34.
15. Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, Brummer N. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels is associated with short survival of patients with colorectal cancer. Clin Cancer Res 2000 6 : 4292 9.
16. Ylisirniö S, Höyhtyä M, Turpeeniemi-Hujanen T. Serum matrix metalloproteinases-2, -9 and tissue inhibitors of metalloproteinases-1, -2 in lung cancer - TIMP-1 as a prognostic marker. Anticancer Res 2000 20 : 1311 6.
17. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996 7 : 2379 87.
18. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Serum matrix metalloproteinase-9 in head and neck squamous cell carcinoma is a prognostic marker. Int J Cancer 2005 116 : 422 7.
19. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue inhibitor of Matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005 11 : 3257 64.
20. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003 106 : 745 51.
21. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T. Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin′s lymphoma. Eur J Haematol 2002 69 : 205 12.
22. Kuittinen O, Apaja-Sarkkinen M, Turpeenniemi-Hujanen T. Gelatinases (MMP-2, MMP-9), TIMP-1 expression and extent of neovascularization in aggressive non-Hodgkin′s lymphomas. Eur J Haematol 2003 71 : 91 9.
23. Sakata KI, Satoh M, Someya M, et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 2004 2 : 356 65.
24. Kossakowska AE, Stefan J, Urbanski J, Edwards DR. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin′s lymphomas. Blood 1991 11 : 2475 81.
25. Kossakowska AE, Urbanski SJ, Huchcroft SA, Edwards DR. Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol Res 1992 4 : 233 40.
26. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. CNI Sponsored International Working Group. J Clin Oncol 1999 19 : 1244 53.
27. Gentilini F, Calzolari C, Turba ME, Agnoli C, Fava D, Forni M, Bergamini PF. Prognostic value of serum vascular endothelial growth factor (VEGF) and plasma activity of matrix metalloproteinase (MMP) 2 and 9 in lymphoma-affected dogs. Leuk Res 2005 29 : 1263 9.
28. Kossakowska AE, Urbanski SJ, Watson A, Hayden LJ, Edwards DR. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol Res 1993 5 : 19 28.
29. Lalancette M, Aoudjit F, Potworowski EF, St-Pierre Y. Resistance of ICAM-1 deficient mice to metastasis overcome by increases aggressiveness of lymphoma cells. Blood 2000 95 : 314 9.
30. Aoudjit F, Masure S, Opdenakker G, Potworowski EF, St-Pierre Y. Gelatinase B (MMP-9), but not its inhibitor (TIMP-1), dictates the growth rate of experimental thymic lymphoma. Int J Cancer 1999 82 : 743 7.
31. Pennanen H, Kuittinen O, Soini Y. Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma. Eur J Haematol 2004 72 : 1 9.
32. Choi JW, An JS, Lee JH, Lee ES, Kim KH, Kim YS. Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. Mod Pathol 2006 19 : 963 73.
33. Hoikkala S, Pääkkö P, Soini Y, Mäkitaro R, Kinnula V, Turpeeniemi-Hujanen T. Tissue MMP-2 and MMP-9 are better prognostic factors than serum MMP-2/TIMP-2 complex or TIMP-1 in Stage I-III lung carcinoma. Cancer Lett 2006 236 : 125 32.
34. Kuvaja P, Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Low serum level of pro-matrix metalloproteinase 2 correlates with aggressive behavior in breast carcinoma. Hum Pathol 2006 37 : 1316 23.
35. Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma - tissue immunoreactivity predicts aggressive clinical course. Mod Pathol 2006 19 : 208 17.
36. Tuhkanen H, Anttila M, Kosma V-M, Yla-Herttuala S, Heinonen S, Kuronen A, Juhola M, Tammi R, Tammi M, Mannermaa A. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3P. Int J Cancer 2004 109 : 247 52.
37. Tuhkanen H, Anttila M, Kosma V-M, Heinonen S, Juhola M, Helisalmi S, Kataja V, Mannermaa A. Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas. Int J Cancer 2006 119 : 1345 53.
38. Hazar B, Polat G, Seyrek E, Bagdatoglglu O, Kanik A, Tiftik N. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin′s lymphoma. Int J Clin Pract 2004 58 : 139 43.